Palvella Therapeutics, Inc. Common Stock Earnings Dividend
Earnings Summary
Revenue | $0Mn |
Net Profits | $-21.87Mn |
Net Profit Margins | -Inf% |
Palvella Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Palvella Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.
Palvella Therapeutics, Inc. Common Stock’s net profit fell -130.92% since last year same period to $-21.87Mn in the Q2 2026. On a quarterly growth basis, Palvella Therapeutics, Inc. Common Stock has generated -38.71% fall in its net profits since last 3-months.
Palvella Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Palvella Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
EPS Estimate Current Quarter | -1.63 |
EPS Estimate Current Year | -1.63 |
Palvella Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -1.63 - a -40.52% fall from last quarter’s estimates.
Palvella Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -1.63.
Key Ratios
Earning Per Share (EPS) | -1.52 |
Palvella Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -76.74% since last year same period to -1.52 in the Q2 2026. This indicates that the Palvella Therapeutics, Inc. Common Stock has generated -76.74% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2026-08-04 | -1.16 | -1.52 | -31.03% |
2026-05-07 | -0.93 | -1.2 | -29.03% |
